M-L. Tanguy

658 total citations
13 papers, 170 citations indexed

About

M-L. Tanguy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, M-L. Tanguy has authored 13 papers receiving a total of 170 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in M-L. Tanguy's work include Colorectal Cancer Treatments and Studies (3 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Renal cell carcinoma treatment (2 papers). M-L. Tanguy is often cited by papers focused on Colorectal Cancer Treatments and Studies (3 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Renal cell carcinoma treatment (2 papers). M-L. Tanguy collaborates with scholars based in France, Belgium and Switzerland. M-L. Tanguy's co-authors include François Doz, Jean Claude Gentet, Dominique Plantaz, S. Neuenschwander, Pierre Validire, Hélène Pacquement, Éric Bouffet, Laurence Desjardins, J. P. Vannier and Jean‐Michel Zucker and has published in prestigious journals such as Neurology, Cancer Research and Journal of Hepatology.

In The Last Decade

M-L. Tanguy

11 papers receiving 167 citations

Peers

Countries citing papers authored by M-L. Tanguy

Since Specialization

Citations

This map shows the geographic impact of M-L. Tanguy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M-L. Tanguy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M-L. Tanguy more than expected).

Fields of papers citing papers by M-L. Tanguy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M-L. Tanguy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M-L. Tanguy. The network helps show where M-L. Tanguy may publish in the future.

Co-authorship network of co-authors of M-L. Tanguy

This figure shows the co-authorship network connecting the top 25 collaborators of M-L. Tanguy. A scholar is included among the top collaborators of M-L. Tanguy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M-L. Tanguy. M-L. Tanguy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	12P ORGANOTREAT-01: A pioneer phase I/II multicenter trial of organoid-driven precision medicine for refractory colorectal cancer 2025 ·Annals of Oncology ·Fanny Jaulin, Jérôme Cartry, (unknown), M-L. Tanguy, (unknown), (unknown), Maxime Annereau, Valérie Boige, (unknown), (unknown), Thierry de Baère, (unknown), Damien Botsen, Diane Pannier, (unknown), (unknown), (unknown), David Malka, Alice Boilève, (unknown)	1
2	Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study 2024 ·BMC Cancer ·(unknown), (unknown), (unknown), Cristina Smolenschi, M-L. Tanguy, (unknown), David Malka, T. Pudlarz, Alina Fuerea, (unknown), Antoine Hollebecque, Michel Ducreux, Alice Boilève	3
3	3O PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC) 2024 ·Annals of Oncology ·Michel Ducreux, Méher Ben Abdelghani, David Tougeron, (unknown), (unknown), F. Khemissa Akouz, J. Martin-Babau, (unknown), Clélia Coutzac, H. Castanie, Julien Taı̈eb, Jean–Marc Phelip, Nadim Farés, Wulfran Cacheux, (unknown), Damien Botsen, (unknown), M. Chevrot, M-L. Tanguy, Aurélie Parzy	1
4	SO-1 Clinical and molecular features of patients with KRAS wild-type pancreatic adenocarcinoma 2022 ·Annals of Oncology ·(unknown), (unknown), Antoine Hollebecque, M-L. Tanguy, (unknown), David Malka, Cristina Smolenschi, Michel Ducreux, Alice Boilève	1
5	508TiP PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC) 2021 ·Annals of Oncology ·Michel Ducreux, Aurélie Parzy, Méher Ben Abdelghani, J. Martin-Babau, David Tougeron, Damien Botsen, Julien Taı̈eb, Diane Pannier, Faïza Khemissa, (unknown), Anne-Laure Villing, Olivier Bouché, (unknown), (unknown), (unknown), M-L. Tanguy, (unknown)	1
6	Abstract P3-12-06: TOxicities of Locoregional Radiotherapy Associated with Bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation 2019 ·Cancer Research ·(unknown), M-L. Tanguy, P. Cottu, (unknown), P. Bontemps, C. Lemanski, Pierre Baumann, Christelle Lévy, Karine Peignaux, A. Reynaud-Bougnoux, (unknown), (unknown)	0
7	Plasma microvesicles levels can predict the development of hepatocellular carcinoma in patients with cirrhosis 2017 ·Journal of Hepatology ·(unknown), Audrey Payancé, Julien Bissonnette, M-L. Tanguy, Olivier Roux, Mohamed Bouattour, Olivier Soubrane, Claire Francoz, Didier Lebrec, Valérie Vilgrain, Valérie Paradis, Dominique Valla, François Durand, Chantal M. Boulanger, Pierre‐Emmanuel Rautou	2
8	2904 Patterns of response and relapse of primary central nervous system lymphomas (PCNSL) following first line of high-dose methotrexate-based chemotherapy (hdMTX): Independent review of a prospective ANOCEF randomized phase II trial 2015 ·European Journal of Cancer ·Émeline Tabouret, Caroline Houillier, N. Martin–Duverneuil, Marie Blonski, Carole Soussain, Hervé Ghesquières, Roch Houot, Vincent Delwail, Pierre Soubeyran, Rémy Gressin, Emmanuel Gyan, (unknown), Olivier Chinot, Luc Taillandier, M-L. Tanguy, (unknown), Khê Hoang‐Xuan	1
9	A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society 2003 ·Bone Marrow Transplantation ·Hélène Espérou, JM Boiron, JM Cayuela, Odile Blanchet, Mathieu Kuentz, J P Jouet, Nöel Milpied, J Cahn, Catherine Faucher, J-H Bourhis, Mauricette Michallet, M-L. Tanguy, Vernant Jp, J Gäbert, Pierre Bordigoni, Norbert Ifrah, André Baruchel, Hervé Dombret, (unknown)	44
10	Telomerase reactivation in malignant gliomas and loss of heterozygosity on 10p15.1 2003 ·Neurology ·Pascal Leuraud, Lucinda Aguirre‐Cruz, Khê Hoang‐Xuan, Emmanuelle Crinière, M-L. Tanguy, J.-L. Golmard, M. Kujas, J. Delattre, Marc Sanson	3
11	Prior treatment with alpha interferon does not adversely  affect the outcome of allogeneic transplantation  for chronic myeloid leukaemia 2002 ·British Journal of Haematology ·Arnaud Pigneux, M-L. Tanguy, Mauricette Michallet, J P Jouet, Mathieu Kuentz, Vernant Jp, Nöel Milpied, Norbert Ifrah, J Cahn, N Gratecos, Oumédaly Reman, H. Curé, Denis Caillot, Francis Witz, (unknown), P Tron, Josy Reiffers, (unknown)	15
12	High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study 1997 ·European Journal of Cancer ·(unknown), François Doz, M-L. Tanguy, E. Quintana, Jean Michon, Hélène Pacquement, Éric Bouffet, Jean Claude Gentet, Dominique Plantaz, P Lutz, J. P. Vannier, Pierre Validire, S. Neuenschwander, Laurence Desjardins, Jean‐Michel Zucker	98
13	Peripheral blood progenitor cell transplantation in France. 1995 ·PubMed ·Josy Reiffers, C. Fabères, M-L. Tanguy	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact